9th International Conference on Bipolar Disorder, June 9-11, 2011, David L. Lawrence Convention Center, Pittsburgh, PA


Home Presentations Faculty Posters Lilly Fellowship Travel & Hotel CDI 2011 Contact Links ICBD Archives UPMC Psychiatry

 

Course Directors

Ellen Frank, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Samuel Gershon, MD
Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

David J. Kupfer, MD
University of Pittsburgh School of Medicine
Pittsburgh Pennsylvania

Michael E. Thase, MD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania



International Planning Committee


Michael Berk, MD, PhD
University of Melbourne
Melbourne, Australia

Valentim Gentil, MD, PhD
University of Sao Paulo Medical School
São Paulo, Brazil

Giovanni de Girolamo, MD

Saint John of God Clinical Research Centre
Brescia, Italy

Guy Goodwin, DPhil, FMedSci
University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom

Fouzia Laghrissi-Thode, MD
F. Hoffmann-La Roche Ltd.
Basel, Switzerland
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Marion Leboyer, MD, PhD
Hôpital Chenevier-Mondor
Universite Paris XII 
Créteil, France

Bruno Muller-Oerlinghausen, DrMed
Drug Commission of the German Medical Association
Freie Universitaet Berlin
Berlin, Germany

Mauricio Tohen, MD, DrPH, MBA
University of Texas Health Science Center
San Antonio, Texas

Eduard Vieta, MD, PhD
University of Barcelona
Barcelona, Spain

Lakshmi N. Yatham, MB, FRCPC
University of British Columbia
Vancouver, British Columbia, Canada


FACULTY

 
   

Jules Angst, MD
Zurich University Psychiatric Hospital
Zurich, Switzerland
 

David A. Axelson, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Michael Berk, MD, PhD

University of Melbourne
Melbourne, Australia

Toni R. Ballard, MA

Allegheny Family Network
Pittsburgh, Pennsylvania

Mark S. Bauer, MD

Harvard Medical School
VA Boston Healthcare System
Boston, Massachusetts


Boris Birmaher, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

 

Corin Bourne, PhD
University of Oxford
Warneford  Hospital
Oxford, United Kingdom
 

Charles L. Bowden, MD
University of Texas Health Science Center
San Antonio, Texas



Joseph Calabrese, MD
Case Western Reserve University School of Medicine
Cleveland, Ohio 

Gabrielle A. Carlson, MD
Stony Brook University School of Medicine
Stony Brook, New York


Francesc Colom, PsyD, MSc, PhD
University of Barcelona
Barcelona, Spain Nancy DiazGranados, MD, MS
University of Texas Health Science Center
San Antonio, Texas
Faith Dickerson, PhD, MPH Sheppard Pratt Health System Baltimore, Maryland

Brent Forester, MD
Harvard Medical School
Boston, Massachusetts

Sophia Frangou, MD, PhD
Institute of Psychiatry
Kings College London
London, United Kingdom


Ellen Frank, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Debra Frankel, DCSW
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Mark A. Frye, MD
Mayo College of Medicine
Rochester, Minnesota

John Geddes, MD, FRC Psych
University of Oxford
Warneford Hospital
Oxford, United Kingdom

Elizabeth L. George, PhD

University of Colorado at Boulder
Boulder, Colorado

Samuel Gershon, MD
Leonard M. Miller School of Medicine
University of Miami
Miami, Florida


S. Nassir Ghaemi, MD, MPH
Tufts University School of Medicine
Boston, Massachusetts


Ariel G. Gildengers, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Benjamin I. Goldstein, MD
University of Toronto Faculty of Medicine,
Toronto, Ontario, Canada


Jodi M. Gonzalez, PhD

University of Texas Health Science Center
San Antonio, Texas


Guy Goodwin, DPhil, FMedSci
University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom


Paul Grof, MD, PhD, FRCPC
Mood Disorders Centre of Ottawa
Ottawa, Ontario, Canada
and University of Toronto
Toronto, Ontario, Canada


Allison Harvey, PhD
University of California at Berkeley
Berkeley, California

Roger F. Haskett, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania


Chantal Henry, MD, PhD
Hôpital Chenevier-Mondor
Universite Paris XII 
Créteil, France


Amir Kalali, MD
Quintiles 
San Diego, California
 

Terence Ketter, MD
Stanford University School of Medicine
Palo Alto, California

Amy M. Kilbourne, PhD, MPH
University of Michigan
Ann Arbor, Michigan

Fouzia Laghrissi-Thode, MD

F. Hoffmann-La Roche Ltd.
Basel, Switzerland
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Marion Leboyer, MD, PhD
Hôpital Chenevier – Mondor
Universite Paris XII 
Créteil, France

Andrew C. Leon, PhD
Weill Cornell Medical College
White Plains, New York

David A. Lewis, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Gin Malhi, MBChB, MRCPsych, FRANZCP, MD
The University of Sydney
Sydney, Australia

Husseini K. Manji, MD

Johnson & Johnson Pharmaceutical Research and Development
Titusville, New Jersey
Duke University School of Medicine
Durham, North Carolina

David J. Miklowitz, PhD
David Geffen School of Medicine at UCLA
Los Angeles, California

Andrew A. Nierenberg, M.D.
Harvard Medical School
Boston, Massachusetts

Dost Ongϋr, MD, PhD
Harvard Medical School
Boston, Massachusetts


Michael J. Ostacher, MD, MPH
Stanford University School of Medicine
Palo Alto, California

Mary L. Phillips, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Noreen Reilly-Harrington, PhD
Harvard Medical School
Boston, Massachusetts

Martha Sajatovic, MD
Case Western Reserve University School of Medicine
Cleveland, Ohio

Etienne Sibille, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Maria Silva
Allegheny Family Network
Pittsburgh, Pennsylvania


Stephen M. Strakowski, MD
University of Cincinnati Academic Health Center
Cincinnati, Ohio

Trisha Suppes, MD, PhD 
Stanford University School of Medicine
Palo Alto, California

Holly A. Swartz, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Michael E. Thase, MD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Mauricio Tohen, MD, DrPH, MBA
University of Texas Health Science Center
San Antonio, Texas

Bryan K. Tolliver, MD, PhD

Medical University of South Carolina
Charleston, South Carolina


Eduard Vieta, MD, PhD
University of Barcelona
Barcelona, Spain

Adele Viguera, MD
Cleveland Clinic Main Campus
Cleveland, Ohio

Nora D. Volkow, MD
National Institute on Drug Abuse
Rockville, Maryland

Katherine L. Wisner, MD, MS
University of Pittsburgh School of  Medicine
Pittsburgh, Pennsylvania

Lakshmi N. Yatham, MB, FRCPC
University of British Columbia
Vancouver, British Columbia, Canada

Robert H. Yolken, MD

The Johns Hopkins University School of Medicine
Baltimore, Maryland


L. Trevor Young, MD, PhD, FRCPC  
University of Toronto
Toronto, Ontario, Canada

Carlos A. Zarate, MD
National Institute of Mental Health
Bethesda, Maryland

 

BIOGRAPHICAL SKETCHES

COURSE DIRECTORS

 

Ellen Frank, PhD
Distinguished Professor of Psychiatry and Professor of Psychology
University of Pittsburgh School of Medicine
Director, Depression and Manic Depression Prevention Program
Western Psychiatric Institute and Clinic, Pittsburgh, PA

Ellen Frank, Ph.D. is Distinguished Professor of Psychiatry and Professor of Psychology at the University of Pittsburgh School of Medicine and Director of the Depression and Manic Depression Prevention program at Western Psychiatric Institute and Clinic.

Under a MERIT award from the National Institute of Mental Health (NIMH) Dr. Frank and her colleagues developed a new psychotherapy—interpersonal and social rhythm therapy (IPSRT) —for the treatment of manic-depressive illness that has been implemented across the US and around the world IPSRT has now been adapted for both group and individual treatment of both bipolar and unipolar disorders. She recently completed a study with researchers at the University of Pisa, Italy, aimed at achieving a better understanding of the clinical importance of subsyndromal mood and anxiety conditions and their impact on the outcome of treatments for depression.

An expert in mood disorders and their treatment, Dr. Frank has served as Chair of the Food and Drug Administration Psychopharmacologic Drugs Advisory Panel and as a member of the U.S. National Advisory Mental Health Council. She currently serves on the Mood Disorders Workgroup of the American Psychiatric Association Task Force on DSM-5 and is an Honorary Fellow of the American Psychiatric Association. In 1999, Dr. Frank was elected to the National Academy of Sciences Institute of Medicine.

A prolific writer, Dr. Frank has published over 390 peer-reviewed papers and more than 100 books and book chapters.

Dr. Frank graduated from Vassar College, earned a master’s degree in English at Carnegie Mellon University and her doctorate in psychology at the University of Pittsburgh.


Samuel Gershon, MD
Vice Chairman, Academic Affairs, Department of Psychiatry, University of Miami, Miami, Florida
Emeritus Professor of Psychiatry, University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Dr. Samuel Gershon joined the faculty at the University of Pittsburgh in April 1988, as Associate Vice Chancellor for Research in the Health Sciences, and Associate Research Director for the Neurosciences in the Department of Psychiatry. He stepped down from this position in 1995 and assumed the position of Chairman of the Institutional Review Board, University of Pittsburgh. Prior to his tenure with the University of Pittsburgh, Dr. Gershon was Director of the Neuropsychopharmacology Research Unit at New York University for 16 years. He then assumed the position of Professor and Chairman of the Department of Psychiatry at Wayne State University and was also the Director of the Lafayette Clinic. He was a longtime recipient of NIH Research Support during his years as an investigator.
Dr. Gershon’s career as a psychiatrist and investigator spans more than 50 years. During this time he has published more than 600 writings and has won several prestigious awards including, among others, the Pfizer Scholarship for Medical Research Overseas, the American Psychiatric Association’s Rush Gold Medal Award, the 6th ICBD Mogens Schou Award for Distinguished Service, and in 2008 the CINP Pioneer Award in Neuropsychopharmacology. His area of specific interest and work encompasses psychopharmacological interest in various psychiatric areas. He is currently the Co-Editor of Bipolar Disorders – An International Journal of Psychiatry and Neurosciences and has been since its inception in 1998. He is also a founding Councilor of the International Society for Bipolar Disorders and served as President from 2001-2005. He is currently at the Department of Psychiatry, University of Miami.



David J. Kupfer, MD
Thomas Detre Professor, Department of Psychiatry, University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA

David J. Kupfer, M.D., is the Thomas Detre Professor of the Department of Psychiatry at the University of Pittsburgh School of Medicine. He is also a Professor of Neuroscience at the University of Pittsburgh School of Medicine. His previous appointments include Chairman of the Department of Psychiatry of the University of Pittsburgh School of Medicine (1983-2009), Medical Director of Western Psychiatric Institute and Clinic (2001-2009), positions at Yale University, Griffin Hospital, New Fairview Hall Convalescent Hospital and the National Institute of Mental Health. Academically, Dr. Kupfer received his bachelor’s (magna cum laude) and M.D. degrees from Yale University. Following completion of an internship, Dr. Kupfer continued his postgraduate clinical and research training at the Yale New Haven Hospital and at the National Institute of Mental Health (NIMH). In 1970, he was appointed an assistant professor of psychiatry at Yale University School of Medicine. Dr. Kupfer joined the faculty at the University of Pittsburgh in 1973 as an associate professor of psychiatry and director of research and research training at Western Psychiatric Institute and Clinic. He was promoted to professor of psychiatry in 1975 and became Chairman of the department in 1983. He promoted widespread collaborations between clinical investigators in psychiatry and those in more basic neurosciences. Under Dr. Kupfer’s direction, WPIC has become one of the nation’s preeminent university-based psychiatric centers as evidenced by the quality and number of publications as well as the amount of peer-reviewed federal funding for mental health research. He has written more than 1000 articles, books, and book chapters that examine treatment in recurrent depression, the causes of depression, and the relationship between biomarkers and depression.

In recognition of his contributions to the field, Dr. Kupfer has been the recipient of numerous awards and honors including the A.E. Bennett Research Award in Clinical Science (1975), the Anna-Monika Foundation Prize (1977), the Daniel H. Efron Award (1979), the Twenty-Sixth Annual Award of the Institute of Pennsylvania Hospital in Memory of Edward A. Strecker, M.D. (1989), the William R. McAlpin, Jr, Research Achievement Award (1990), the 1993 American Psychiatric Association Award for Research in Psychiatry, the First Isaac Ray Decade of Excellence Award (1994), the Twelfth Annual Edward J. Sachar Award (1996), the 1996 Gerald Klerman Lifetime Research Award (jointly with Dr. Ellen Frank), the Institute of Medicine’s 1998 Rhoda and Bernard Sarnat International Prize in Mental Health, and the American Psychopathological Association’s 1999 Joseph Zubin Award (jointly with Dr. Ellen Frank). He was elected to the Institute of Medicine of the National Academy of Sciences in 1990. Dr. Kupfer is the Founding President of the International Society of Bipolar Disorders. Most recently, he was the 2010 Litchfield lecturer at the Department of Psychiatry at Oxford University. Dr. Kupfer chairs the American Psychiatric Association’s Task Force for DSM-5.
 



Michael E. Thase, MD
Professor of Psychiatry, University of Pennsylvania School of Medicine
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA

Michael E. Thase, M.D., joined the faculty of the University of Pennsylvania School of Medicine in January, 2007 as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic. Dr. Thase’s research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, a member of the Board of Directors of the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.


FACULTY

Jules Angst, MD
Emeritus Professor of Psychiatry, Zurich University, Zurich, Switzerland

Jules Angst, MD, is Emeritus Professor of Psychiatry at Zurich University and Honorary Doctor of University of Heidelberg (Germany). He was Professor of Clinical Psychiatry and Head of the Research Department of Zurich University Psychiatric Hospital (the Burghölzli) from 1969 to 1994. Since then he has continued his work in epidemiological and clinical research at the University.

Memberships: Jules Angst is an Honorary Fellow of the Royal College of Psychiatrists. He is an Honorary Member of the Mexican, Chilean, Polish, and Austrian Psychiatric Associations; the American Psychopathological Association; the German Association of Biological Psychiatrists, the Swiss Society of Psychiatric Epidemiology; the Swiss Society of Biological Psychiatry, the European College of Neuropsychopharmacology and the Association of European Psychiatrists, of which he was President from 1996 to 1998. In 2002 he was elected fellow of the American Psychiatric Association.

Awards: Jules Angst has received the Anna Monika Award (in1967 and in1969), the Paul Martini Prize for Methodology in Medicine (1969), the Otto Naegeli Prize (1983), the Eric Strömgren Medal (1987), and the Emil Kraepelin Medal of the Max Planck Institute, Munich (1992). He has also received the Selo Prize of NARSAD, USA (1994), the Mogens Schou Award for Research in Bipolar Disorder, USA (2001), the Burghölzli Award for Social Psychiatry (2001), the Lifetime Achievement Award of the International Society of Psychiatric Genetics (2002), the Wagner-Jauregg Medal (2007) and the Juan J. López-Ibor Award (2010).



David A. Axelson, MD
Associate Professor of Psychiatry, University of Pittsburgh School of Medicine
Director of the Child and Adolescent Bipolar Services (CABS) Outpatient Program
Western Psychiatric Institute and Clinic, Pittsburgh, PA

David Axelson, M.D. is an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine and the Director of the Child and Adolescent Bipolar Services (CABS) program at the Western Psychiatric Institute and Clinic. Dr. Axelson received a B.A. in 1987 from Brown University and his M.D. in 1992 from the Duke University School of Medicine. He completed a combined General – Child Psychiatry residency at Western Psychiatric Institute and Clinic in 1997 and a post-doctoral research fellowship in child and adolescent mood disorders at the University of Pittsburgh School of Medicine. Dr. Axelson’s research focuses on the phenomenology, course and treatment of children and adolescents with bipolar spectrum disorders. He received a career development award from the National Institute of Mental Health and is currently a Principal Investigator on a multisite NIMH-funded treatment study of bipolar youth. He is also a Co-Principal Investigator for studies examining the phenomenology of pediatric bipolar disorder and the longitudinal course of the offspring of bipolar parents.


Toni R. Ballard, MA
Supervisor, Allegheny Family Network, Pittsburgh, PA

Toni Ballard has worked in the Social Work field since 1993, providing services to families who have children from birth to our more mature families 60 and over. Toni has held various positions, including those working with families who have Child Welfare involvement to our families that work with the Department of Aging on behalf of their love ones. Toni has provided direct care to families and has held several management positions throughout her career. Toni received her Bachelor’s Degree from Lincoln University and her Master’s Degree from Carlow University. She believes that every family has strengths and she understands that families generally want the best for their loved ones and sometimes with a little help can overcome all obstacles.

Currently, she is a credentialed Coach/Supervisor in High Fidelity Wraparound. She was the first credentialed Family Support Role Coach in the Country. In her current position, she supervises Family Support Partners who work in High Fidelity Wraparound who provide support to families raising children with MH, Emotional or Behavioral Concerns.


Mark S. Bauer, MD
Professor of Psychiatry, Harvard Medical School
Associate Director, Center for Organization, Leadership, & Management Research (COLMR)
Boston VA Healthcare System, Boston, MA

Dr. Bauer’s research focus for the last decade has been on developing, testing, and implementing collaborative chronic care models to improve evidence-based treatment delivery for manic-depressive disorder and other serious mental illnesses. He has pioneered the development of self-management skill enhancement methodologies for individuals with bipolar disorder through the portfolio of Life Goals treatments. He has also contributed to research on the nosology, assessment, and treatment of bipolar disorder particularly rapid cycling.

Dr. Bauer received his bachelor’s degree from the University of Chicago and medical degree from the University of Pennsylvania. He has also served on the faculties of psychiatry and pharmacology at the University of Pennsylvania and the faculty of psychiatry at Brown University. He is the author of over 100 peer-reviewed research articles and author or editor of 6 books. He has won awards for excellence research, teaching, clinical care, and administration. He has been named Distinguished Fellow of the American Psychiatric Association and in 2011 received the Klerman Senior Investigator Award from the Depression and Bipolar Support Alliance.


Michael Berk, MD, PhD
Chair of Psychiatry for Barwon Health and The Geelong Clinic
University of Melbourne, Melbourne, Australia

Professor Michael Berk is currently appointed as Chair of Psychiatry in the School of Medicine, Deakin University. He also is a Professorial Research fellow at the University of Melbourne and the Mental Health Research Institute, and leads the first episode bipolar program at Orygen Youth Health. He is immediate past President of the International Society of Bipolar Disorders, and Chairman of the Australasian Society of Bipolar Disorders. He has published over 350 papers on a range of topics with his research interests focusing on mood and psychotic disorders, particularly bipolar disorder and depression. His greatest contribution to the field is in the discovery and implementation of novel therapies. He has published over 20 self-initiated, non-industry randomised controlled trials, predominantly in bipolar disorder. He is a past committee member of both the Collegium Internationale Psychopharmacologicum and World Federation of Societies of Biological Psychiatry is a member of a number of international advisory boards. He was the founding editor of The Journal of Depression and Anxiety, is associate editor of both the Australian and New Zealand Journal of Psychiatry and Early Intervention in Psychiatry, has served as guest editor or is on the editorial board of 12 other journals as well as being a reviewer of 30 journals.

He is the recipient of a number of grants, including a NHMRC CCRE and 3 NHMRC project grants, two beyondblue grants and two Stanley Medical Research Institute awards and is a lead investigator on the CRE for Mental Health. He is regularly invited as a speaker at international meetings. In 2008, he was awarded the Australasian Society of Psychiatric Research Eli Lilly Oration, the Pathcare Smart Geelong Research and Learning Expo Health and Lifestyle award and the G Force Recruitment Researcher Of The Year award for this work, and in 2009 received a commendation in the Ministers Award for Mental Health. Since relocating to Australia in 2001, he has established a new research unit at Barwon Health, which now has 15 researchers and 6 students engaged in 33 projects, multiple, local national and international collaborations, as well as heading a clinical Professorial Unit at the Geelong Clinic.


Boris Birmaher, MD
Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry
University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA

Boris Birmaher, MD, is the Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry at the University of Pittsburgh, School of Medicine. He has board certifications in both general psychiatry and child psychiatry. He received his medical degree from Valle University in Cali, Colombia and completed; training in general psychiatry at the Hebrew University, Hadassah Medical Center in Jerusalem, Israel; training in biological psychiatry at the Albert Einstein College of Medicine in New York; and training in child psychiatry at Columbia University, New York Psychiatric Institute in New York.

Dr. Birmaher has been involved in clinical work and research in pediatric mood and anxiety disorders for over 25 years. His research interests include areas of phenomenology, course and outcome, etiology, and pharmacology and psychosocial treatments. He is currently involved in several NIMH studies including: 1) “Course and Outcome for Adolescents with Bipolar Illness,” aimed at describing the phenomenology, course, and associated factors in children and adolescents with bipolar spectrum disorder; 2) “Children of Bipolar Parents: A High Risk Follow-up Study,” aimed at studying the longitudinal psychopathology of children of parents with bipolar disorder compared with children of community controls; and 3) “Longitudinal Assessment of Manic Symptoms,” aimed at evaluating the predictive value of early-onset manic symptoms in a large sample of children ages 6-12 years old. Together with Dr. David Axelson, Dr. Birmaher is the Co-Director of the Child and Adolescent Bipolar Services (CABS) program, a program for the service, teaching and research of bipolar disorder in youth.


Corin Bourne, DPhil
Post-Doctoral Researcher, Department of Psychiatry, University of Oxford
Warneford Hospital, Oxford, United Kingdom

Corin Bourne holds bachelor degrees in Engineering (Loughborough University of Science and Technology) and Psychology (University College London, UCL) as well as a DPhil from the University of Oxford. Supported by a Medical Research Council (MRC) scholarship, Corin’s DPhil research used fMRI and other techniques to investigate the peri-traumatic cognitive mechanisms involved in the formation of intrusive memories of traumatic events. Corin is currently employed on a project funded by the 7th Framework of the European Commission: the European Network of Bipolar Research Centres (ENBREC). ENBREC has been established to develop and implement common tools and practices in the diagnosis, assessment, care, and treatment of bipolar disorder across Europe. Within ENBREC, the Oxford team has specific responsibility for neuropsychological assessment of cognitive deficits associated with bipolar disorder. Corin’s research interests are broad but are centred on the interface between cognitive and clinical psychology; in understanding how specific cognitions and cognitive processes contribute to the development and maintenance of clinical disorders.


Charles L. Bowden, MD
Nancy U. Karren Professor, Department of Psychiatry
University of Texas Health Science Center, San Antonio, Texas

Charles L. Bowden, MD is Nancy U. Karren Clinical Professor in the Department of Psychiatry and Professor in the Department of Pharmacology at The University of Texas Health Science Center at San Antonio. He completed his training in psychiatry at the New York State Psychiatric Institute and Columbia-Presbyterian Hospital in New York, New York.

Dr. Bowden was awarded the 2001 Gerald L. Klerman Senior Investigator Award by the Depression and Bipolar Support Alliance, received the 2006 Mind of America Scientific Research Award from the National Alliance for the Mentally Ill and the 2008 NARSAD Falcone prize for outstanding achievement in affective disorders research. Dr. Bowden is a Fellow of the American College of Neuropsychopharmacology, the Collegium Internationale Neuro-Psychopharmacologicum and a Corresponding Member of the European College of Neuropsychopharmacology and a member of the Executive Committee of the International Society for CNS Clinical Trials and Methodology. He is Associate Editor for Acta Psychiatrica Scandinavica. He has authored more than 400 publications. His research is principally on the symptomatic and biological characterization of bipolar disorders and the effectiveness and pharmacodynamics of mood stabilizing drugs. He has been principal investigator for 90 studies funded by pharmaceutical companies, NIMH, and various foundations. Dr. Bowden frequently serves as consultant to pharmaceutical companies and governmental agencies and is named in Best Doctors in the US in the area of mood disorders.


Joseph Calabrese, MD
Bipolar Disorders Research Chair and Professor of Psychiatry, Case Western Reserve University
Director, Mood Disorders Program at the University Hospitals Case Medical Center, Cleveland, Ohio

Joseph Calabrese holds the Bipolar Disorders Research Chair and is Professor of Psychiatry at Case Western Reserve University. He is the Director of the Mood Disorders Program at the University Hospitals Case Medical Center in Cleveland, Ohio. Dr. Calabrese also co-directs an NIMH-funded ‘Bipolar Disorders Research Centre, whose projects include research conducted by Bob Findling (Director of Child and Adolescent Psychiatry) on the phenomenology and treatment of juvenile bipolar, and research conducted by Martha Sajatovic (Director of Geriatric Psychiatry), whose projects include late life bipolar disorder, health services research, and qualitative methodology.
The research center is dedicated to the improvement of clinical outcomes in under-served populations of bipolar disorder, including those with bipolar depression, rapid cycling, children and adolescents, adults currently abusing alcohol and/or drugs, forensic complications of bipolar disorder, those receiving care within community mental health centres, older adults, and members of the Ohio National Guard.
Dr Calabrese has received numerous research grants from the NIMH and Federal agencies and published over 300 peer-reviewed papers. His primary scientific focus is the short- and long-term treatment of bipolar disorder, with special emphasis on bipolar depression and the rapid cycling pattern of presentation. Dr. Calabrese was chosen by psychiatry residents to receive the ‘Best Teacher of the Year Award’ in three different years, received the NARSAD Lifetime Achievement Award for his research in bipolar disorder in 2005, Ellis Island Medal of Honor in 2006, and the Gerald L. Klerman Lifetime Achievement Award in 2008.


Gabrielle A. Carlson, MD
Professor of Psychiatry and Pediatrics and Director of the Division of Child and Adolescent Psychiatry
State University of New York at Stony Brook

Gabrielle A. Carlson, M.D., has been professor of Psychiatry and Pediatrics and Director of the Division of Child and Adolescent Psychiatry at State University of New York at Stony Brook since 1985. She did her undergraduate training at Wellesley and subsequently obtained her MD degree from Cornell University Medical College. She did her adult psychiatry training at Washington University in St. Louis and at the National Institutes of Mental Health. She completed a fellowship in Child and Adolescent Psychiatry at UCLA where she subsequently taught on the faculty.

Dr. Carlson specializes in childhood psychopathology and psychopharmacology in general, and the subjects of childhood and adolescent depression and bipolar disorder, specifically. She has written over 200 papers and chapters on those subjects and has co-authored two books, Affective Disorders in Childhood Adolescence (Spectrum Publications) and Psychiatric Disorders in Children and Adolescents (W.B. Saunders). Her research interests include the phenomenology and long term follow up of young people with bipolar disorder, and the relationship of behavior disorders, developmental disorders and mood disorders. Her most recent grants have focused on those questions.

Dr. Carlson is active in the psychiatry community. She has served on many national committees, editorial boards and various review committees for the National Institute of Mental Health. She has been named in Best Doctors in America, New York City and Long Island and Good Housekeeping’s Best Mental Health Experts. She was recently awarded the APA’s Blanche F. Ittleson Award for research in child and adolescent psychiatry and the New York Academy of Child and Adolescent Psychiatry’s Hulse Award. She is past president of the International Society for Research in Child and Adolescent Psychopathology and is currently Program Chair for the American Academy of Child and Adolescent Psychiatry.


Francesc Colom, PsyD, MSc, PhD
Head of the Psychoeducation and Psychological Treatments Area
Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University of Barcelona), Spain
Francesc Colom, PsyD, MSc, PhD is the head of the Psychoeducation and Psychological Treatments Area of the Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University of Barcelona). The Barcelona Psychoeducation Program, designed by Dr. Colom and his colleagues, is now the strongest evidence-based psychoeducational program for bipolar patients. His book “Psychoeducation Manual for Bipolar Disorder” has been published in several languages including, English, Spanish, Italian, French, and Polish. He has lectured all over the world and published over one hundred scientific articles with an H index of 32. Dr. Colom has also written twelve books and a number of book chapters. His current research focuses on psychological treatment and its biomarkers of response, treatment adherence, pharmacological issues, cognitive impairment and its remediation and on clinical issues such as predominant polarity, mixed states, and temperament.
He has been a member of the Board of Councilors of the International Society for Bipolar Disorders and a member of the Nomenclature Committee and Chair of the Website Education Committee for the same society. He is also is a member of the Scientific Advisory Panel of the ECNP. In addition, he sits on the editorial board of five international scientific journals and enjoys reviewing articles for more than thirty others. In June, 2007, Francesc Colom was awarded the prestigious “Mogens Schou Award” for the quality of his research.


Nancy DiazGranados, MD, MS
Assistant Professor of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX

Nancy DiazGranados, MD, MS, joined the faculty of the University of Texas Health Science Center at San Antonio in September, 2010 as Assistant Professor of Psychiatry. She has a master’s degree in pharmacology from Thomas Jefferson University and a postdoctoral fellowship in experimental therapeutics from the National Institute of Mental Health in Bethesa, MD. Dr. DiazGranados is a 2001 graduate from the Pontifica Universidad Javeriana School of Medicine in Bogota, Colombia; and has developed a career in mood disorders research. Her research focuses on experimental therapeutics with rapid acting antidepressants for treatment resistant depression, bipolar depression, and suicide ideation.


Faith B. Dickerson, PhD, MPH
Director of Psychology, Sheppard Pratt, Baltimore, MD

Faith Dickerson, Ph.D., M.P.H. is the director of psychology and the head of the Stanley Research Program at Sheppard Pratt in Baltimore, Maryland. She is also a Clinical Associate Professor of Psychiatry at the University of Maryland School of Medicine. She received her Ph.D. from Columbia University. Her research interests focus on bipolar disorder and schizophrenia. She has carried out studies about infectious and inflammatory factors, cognitive functioning, and social outcomes of these disorders. She has also directed clinical trials of novel adjunctive medications and has been an investigator on studies to improve the physical health of persons with serious mental illness and to reduce disability in first episode psychosis. Dr. Dickerson has authored or co-authored one textbook and more than 100 scientific articles and book chapters.


Brent Forester, MD
Director, Mood Disorders Division of the Geriatric Psychiatry Research Program &
Site Director of the Harvard Medical School Psychiatry Clerkship at McLean Hospital, Belmont, MA
Assistant Professor of Psychiatry, Harvard Medical School, Cambridge, MA

Dr. Forester is currently the Director of the Mood Disorders Division of the Geriatric Psychiatry Research Program and the Site Director of the Harvard Medical School Psychiatry Clerkship at McLean Hospital in Belmont, MA and an Assistant Professor of Psychiatry at Harvard Medical School. He completed a Masters of Science Degree in June, 2009 through the joint Harvard - MIT Clinician Investigator Training Program. From September 2002 through June, 2007 Brent served as the Medical Director of the Geriatric Neuropsychiatry Unit at McLean Hospital. Before coming to McLean, he served as the Clinical Director of Geriatric Psychiatry at the Mental Health Center of Greater Manchester (in New Hampshire) and an Assistant Professor of Psychiatry at Dartmouth Medical School focusing on geriatric mental health services research.

Dr. Forester has been a principal investigator in a number of research projects including clinical psychopharmacology trials in bipolar disorder, geriatric depression and the management of agitation in patients with dementia. Upon returning to McLean Hospital in 2002, he began collaborating with the McLean Brain Imaging Center and is now conducting studies utilizing magnetic resonance spectroscopy to study markers of energy metabolism in late life depression and bipolar disorder. In 2009, he received a K23 career development award from the NIMH for a project studying lamotrigine in geriatric bipolar depression which focuses on markers of brain energy metabolism (glutamate, glutamine, lactate, NAA) as predictors of clinical status and treatment response.

Dr. Forester is currently the Vice Chair of the Teaching and Training Committee and member of the Board of Directors of the American Association for Geriatric Psychiatry. He also began a three year term as a Member of the Board of Directors of the Alzheimer’s Association for MA and NH in July, 2009.

Dr. Forester has published a number of articles and book chapters on topics including Geriatric Bipolar Disorder, Brain lithium levels and effects on cognition and mood in Geriatric Bipolar Disorder, the Behavioral and Psychological Symptoms of Dementia and Late Life Psychosis. He is actively involved in teaching Harvard Medical Students and McLean Hospital - Mass General Hospital psychiatry residents.


Sophia Frangou, MD, PhD
Reader in Psychiatry
Institute of Psychiatry, King’s College London, London, UK

Dr. Sophia Frangou is Reader in Psychiatry at the Institute of Psychiatry, Kings College London where she heads the Section of Neurobiology of Psychosis since 1997. Dr. Frangou graduated from the Medical School of the University of Athens, Greece. She then moved to the UK where she trained at the Maudsley Hospital, London. In parallel with her psychiatric training she obtained a Masters Degree in Neuroscience and a doctoral degree from the University of London. Dr. Frangou’s research work focuses on the investigation of the pathophysiological processes underlying psychosis using clinical, cognitive and neuroimaging techniques. Research into the aetiology and pathophysiology of psychosis is vital for providing a theoretical framework for developing long-term treatment strategies. She has received numerous awards including the Psychopharmacology Prize from the Royal College of Psychiatrists. Dr. Frangou is the Editor of “European Psychiatry”, the official Journal of the European Psychiatric Association. She is a Fellow of the Royal College of Psychiatrists and of the European Psychiatric Association. She has served on the Council of the British Association for Psychopharmacology (BAP) and co-authored the BAP guidelines for the treatment of Bipolar Disorder. She is Secretary and founding member of the EPA Section of NeuroImaging and heads the Brain Imaging Network of the European College of Neuropsychopharmacology.


Debra Frankel, LCSW
Depression and Manic Depression Prevention Program
University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA
Debra Frankel is a trainer, supervisor and clinician at the University of Pittsburgh School of Medicine in the Depression and Manic Depression Prevention Program at Western Psychiatric Institute and Clinic. She was originally trained in Interpersonal Psychotherapy in 1985 and has treated numerous mood disorder patients using this modality. Ms. Frankel helped to modify interpersonal psychotherapy for bipolar disorder patients and has been training and supervising clinicians in IPSRT since 1995. She has participated in clinical trials involving both Interpersonal Therapy and Interpersonal Therapy and Social Rhythms Therapy. She serves as a training supervisor for research clinicians. She is a clinical supervisor at the University of Pittsburgh Graduate School in Psychology. She has a private practice specializing in mood and anxiety disorders. She received her undergraduate degree from Kenyon College in 1978 and her master’s degree from Columbia University School of Social Work in 1980.


Mark A. Frye, MD
Chair and Professor of Psychiatry, Department of Psychiatry & Psychology
Director, Integrated Mood Group, Mayo Clinic, Rochester, MN

Dr. Frye is Chair of the Department of Psychiatry & Psychology, Mayo Clinic. He received his medical degree from the University of Minnesota and completed his psychiatric training at the UCLA Neuropsychiatric Institute. He completed a subsequent research fellowship in the Biological Psychiatry Branch at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While at NIMH, his area of research was focusing on the neurobiology of depression and bipolar disorder.

Formerly the Director of the UCLA Bipolar Disorder Research Program (1998-2006), he is now Director of the Integrated Mood Group at Mayo Clinic. His clinical interests are in mood disorders (bipolar disorder, treatment resistant depression) with a research focus in clinical trials, pharmacogenomics, and brain imaging.

He has received numerous honors and awards both as an educator and researcher, including three UCLA departmental medical student and resident teaching awards and the Gerald Klerman Young Investigator Award from the Depression and Bipolar Support Alliance.

His research funding has been from the National Institute of Mental Health (NIMH), National Institute of Alcohol Abuse and Alcoholism (NIAAA), The Stanley Medical Research Institute, The American Foundation for Suicide Prevention, and industry. He is an active author, publishing more than 150 papers in peer-reviewed publications. Dr. Frye is on the Scientific Advisory Committee to the Depression and Bipolar Support Alliance and is the Vice President of Global Outreach for the International Society for Bipolar Disorders.


John R. Geddes, MD, FRCPsych
Professor of Epidemiological Psychiatry, Department of Psychiatry, University of Oxford, Oxford, UK

John R. Geddes is Professor of Epidemiological Psychiatry at University of Oxford, UK. His current research focuses on conducting large scale randomized clinical trials and using research synthesis methods including systematic overviews and meta-analysis to inform clinical practice. Professor Geddes is Director of the Oxford Clinical Trials Unit for Mental Illness. Professor Geddes is Honorary Consultant Psychiatrist at the Oxfordshire and Buckinghamshire Mental Health NHS Foundation Trust where he provides clinical care for patients with mood disorders, specialising in bipolar disorder. Professor Geddes is a Fellow of the Royal College of Psychiatrists and, in 2010 was named Academic Psychiatrist of the Year by the Royal College of Psychiatrists. In 2008, he was awarded an Honorary Fellowship of the American College of Psychiatrists. Professor Geddes has authored or co-authored, more than 150 scientific articles and book chapters and 4 books.


Elizabeth L. George, PhD
Licensed Clinical Psychologist, Research Associate, University of Colorado, Boulder, CO
Dr. George received her bachelor’s degree in English and Psychology at the University of North Carolina in Chapel Hill. She received her Ph.D. in Clinical Psychology from the University of Colorado in Boulder. She completed her residency at the Denver Veterans Administration Medical Center. Dr. George is a research associate at the University of Colorado-Boulder where she provides treatment, supervises, and continues to develop treatment outcome programs.
Dr. George has done extensive research in treatment development for bipolar disorder. She has spent 20 years involved in treatment outcome research for adult and adolescent bipolar disorder. She helped to develop Integrated Family and Individual Treatment (IFIT) for bipolar disorder. She co-wrote the manual for Family Focused Treatment (FFT) for adolescent bipolar disorder. Currently she is involved in an ongoing three site FFT treatment outcome study involving 150 families with an adolescent who has bipolar disorder. Dr. George has co-written a manual on a prevention treatment for youth (9-17) at risk for developing bipolar disorder and is involved in a two site outcome study for the at risk population. Dr. George and Dr. David Miklowitz have written a book for parents entitled The Bipolar Teen: What you can do to help your child and your family (2008) describing identification and treatment of adolescent bipolar disorder. Dr. George also provides trainings and lectures on many aspects of the bipolar condition and its treatment including comorbidity and managing bipolar in the academic environment.
In addition, Dr. George has an active private practice that primarily focuses on prevention and treatment of bipolar II and the bipolar spectrum disorders. She is also the community advisor for the Boulder chapter of the Depression and Bipolar Support Alliance (DBSA). She continues to be interested in finding new ways to understand and treat this medically complicated illness.


S. Nassir Ghaemi, MD, MPH
Director, Mood Disorders and Psychopharmacology Programs, Tufts Medical Center, Boston, MA
S. Nassir Ghaemi MD, MPH is a psychiatric researcher with expertise in bipolar disorder, and training in philosophy and public health. He is the author of A Clinician's Guide to Statistics and Epidemiology in Mental Health: Measuring Truth and Uncertainty, published in 2009 by Cambridge University Press. Previous books he has authored include The Concepts of Psychiatry: A Pluralistic Approach to the Mind and Mental Illness (Baltimore, Maryland: Johns Hopkins University Press, 2003, 2007), as well as the 2nd edition of Mood Disorders: A Practical Guide (Baltimore, Maryland: Lippincott, Williams, and Wilkins; 2003, 2007). He has also published over 100 scientific articles or book chapters, and serves on the editorial board of numerous journals. He also serves on the executive committee of the Association for the Advancement of Philosophy and Psychiatry; is a Distinguished Fellow of the American Psychiatric Association; and has served as chairman of the Diagnostic Guidelines Task Force of the International Society for Bipolar Disorders (2005-2008). Dr. Ghaemi obtained his medical degree at the Medical College of Virginia (MCV) in Richmond, completed a medical internship at Massachusetts General Hospital (MGH) in Boston, psychiatry residency at McLean Hospital in Belmont, Massachusetts, and a research psychopharmacology fellowship in mood disorders at MGH, followed by faculty positions at George Washington University, Harvard Medical School, and Emory University. He also received a Master of Arts degree in philosophy from Tufts University in 2001 and a Master of Public Health degree in the Clinical Effectiveness Program from the Harvard School of Public Health in 2004.


Ariel G. Gildengers, MD
Assistant Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA

Dr. Gildengers is Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine and the Western Psychiatric Institute and Clinic. He is an active clinical investigator, whose research focuses on the assessment and treatment of bipolar disorder in older adults. He graduated from the Massachusetts Institute of Technology and the New Jersey Medical School, and completed his post-graduate medical training at the University of Pittsburgh Medical Center and Western Psychiatric Institute and Clinic. Dr. Gildengers received an NIMH K23 Research Career Award to investigate the relationship between bipolar disorder and cognitive function and is currently the Principal Investigator of a five-year longitudinal study examining cognitive function in older adults with bipolar disorder.


Benjamin I. Goldstein, MD, PhD
Assistant Professor of Psychiatry
University of Toronto Faculty of Medicine and Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Dr. Goldstein was previously at the University of Pittsburgh and the Western Psychiatric Institute and Clinic from 2006-2009 where he retains an adjunct faculty appointment. He completed his medical degree at the University of Calgary in 2001 and psychiatric residency at the University of Toronto in 2006. Dr. Goldstein’s clinical and research efforts focus on children and adolescents with bipolar disorder and offspring of parents with bipolar disorder. His specific interests within this population include substance abuse and medical comorbidity as well as peripheral biomarkers. He has authored more than 40 scientific articles. He is the recipient of several national and international awards including the APA/AstraZeneca Young Minds in Psychiatry Award, the Robinson-Cunningham Award from the American Academy of Child and Adolescent Psychiatry, and the Samuel Gershon Award from the International Society for Bipolar Disorders.


Jodi M. Gonzalez, PhD
Associate Professor, University of Texas Health Science Center in San Antonio, TX

Jodi M. Gonzalez obtained her PhD in Counseling Psychology from the University of North Texas in 1999. Her internship and postdoctoral fellowship were completed at the University of Texas Health Science Center at San Antonio, with an emphasis on clinical research. Dr. Gonzalez joined the faculty as an assistant professor at the University of Texas Health Science Center in San Antonio in the Mood and Anxiety Disorders Division in 2000. She is a recipient of a 2007 NARSAD Young Investigator Award to develop and manualize psychodynamic psychotherapy techniques in complicated bipolar disorder. She is currently involved in several community-based research projects and serves as the chair of the Diversity Committee of the multi-site Bipolar Trials Network. Additional areas of research interest and publications are: psychosocial treatment in bipolar disorder, attitudes toward mental health treatment, adherence to treatments, and the impact of ethnicity/race in each of these areas. She lectures and supervises medical students, psychiatry and psychology residents. In particular, she supervises and teaches in psychotherapy models and treatments. Dr. Gonzalez is a licensed psychologist and provides individual and family psychotherapy for adolescents and adults.


Guy Goodwin, DPhil, FMedSci
W A Handley Professor of Psychiatry, University of Oxford, Oxford, England
Guy Goodwin trained in medicine and completed a DPhil in physiology at Oxford. After training in psychiatry he was for 10 years Clinical Scientist and Consultant Psychiatrist in the MRC Brain Metabolism Unit in Edinburgh. Since 1996 he has been Professor of Psychiatry and head of the University department in Oxford. Dr. Goodwin’s research interests are in the treatment of severe psychiatric illness and the application of neuroscience in understanding the neurobiology of mood disorder. Currently, he is involved in projects on the neurobiology of vulnerability to mood disorder, the psychopharmacology of emotional processing. He has also helped develop the basis for larger scale pragmatic clinical trials in bipolar affective disorder (BALANCE and CEQUEL). Dr. Goodwin has served as a member of the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology, the Clinical fellowships panel and Advisory Board of the MRC and the French ANR. He was president of the British Association for Psychopharmacology 2002-2004, is a Fellow of ACNP and President elect of ECNP. He has published over 300 refereed papers and book chapters. He has acted as a reviewer for numerous journals including the American Journal of Psychiatry, The Archives of General Psychiatry, and Biological Psychiatry. Dr. Goodwin remains directly involved in patient care, almost exclusively focused on bipolar disorders.


Paul Grof, MD, PhD, FRCPC(C)
Director of Mood Disorders Center of Ottawa and Professor of Psychiatry at the University of Toronto, Canada

Paul Grof initially worked as a research psychiatrist in the Psychiatric Research Institute in Prague, and as a fellow in psychoendocrinology of affective disorders in West Germany. Since the fall of l968 Dr. Grof was a research psychiatrist and faculty member at McMaster University, Canada, and spent l977 - l978 as a Visiting Scientist at the National Institute of Mental Health in Bethesda, Maryland. Dr. Grof became Director of Research and Education at a teaching hospital of McMaster University, and l985 -2000 was active as Expert of the World Health Organization and as Visiting Professor at several European Universities. From l988 to 1993 Dr. Grof was Clinical Director of the Royal Ottawa Hospital and subsequently directed there clinical and research activities in mood disorders. Currently he is Director of Mood Disorders Center of Ottawa and Professor of Psychiatry at the University of Toronto. He authored and co-authored over 450 papers and book chapters and 3 books.


Allison G. Harvey, PhD
Professor of Psychology, Department of Psychology, University of California, Berkeley, CA

Allison G. Harvey, PhD., completed her clinical and research training in Sydney, Australia, a post doctoral fellowship and her first faculty position at the University of Oxford before moving to the Psychology Department at UC Berkeley in 2004. Dr. Harvey is a licensed clinical psychologist and she is certified in Behavioral Sleep Medicine. She is also an adjunct professor at the University of Bergen, Norway. Dr. Harvey’s research focuses on understanding the role of sleep disturbance across psychiatric disorders, particularly bipolar disorder. Dr. Harvey has authored over 150 scientific articles and book chapters and authored two books. She has been the recipient of numerous awards, including The Queen’s Trust Award, the Chaim Danielle Award for Traumatic Stress Studies and an Honorary Doctorate from the University of Örebro, Sweden. Dr. Harvey has received research funding from the Royal Society, Wellcome Trust, NARSAD and the National Institutes of Mental Health.


Roger F. Haskett, MD
Professor of Psychiatry
University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA

Dr. Haskett joined the faculty at the University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic in 1992 as Professor of Psychiatry. He received his medical and psychiatric training at the University of Melbourne in Australia, followed by a clinical research fellowship and 11 years on the faculty at the University of Michigan Medical School. Dr. Haskett’s research has addressed the neurobiology and treatment of depression and bipolar disorder, including factors that will improve outcomes after electroconvulsive therapy (ECT). His clinical practice emphasizes the diagnostic evaluation and pharmacologic treatment of patients with severe mood disorders and their frequent need for long-term medical management. Dr. Haskett is a Distinguished Life Fellow of the American Psychiatric Association and a past President of the Pennsylvania Psychiatric Society. Dr. Haskett is a member of the editorial board of the Journal of ECT and has been elected to the membership of the American College of Psychiatrists.


Chantal Henry, MD, PhD
Professor of Psychiatry, University of Paris-EST and Chenevier Hospital, Créteil, France
Chantal Henry, MD, PhD, joined the faculty of the University of Paris-Est in September, 2008 as Professor of Psychiatry after 14 years at the Bordeaux hospital. Dr. Henry’s research focuses on the characterization and treatment of bipolar disorders. She works also on the identification of relevant phenotypes for genetic studies on bipolar disorders. Since 2008, Dr. Henry has been in charge of the organization of French networks of expert centres on bipolar disorders, schizophrenia and Asperger. She coordinates also a European project: ENBREC (European Network of Bipolar Research Expert Centres). Dr. Henry has authored or co-authored more than 100 scientific articles, book chapters and books.


Amir Kalali MD
Professor of Psychiatry, University of California San Diego
Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS
Quintiles Inc., San Diego, CA

Dr. Kalali is currently Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS, at Quintiles Inc., focusing on developing novel compounds for the treatment of disorders of the central nervous system. He is globally responsible for the medical and scientific aspects of development programs in psychiatry and neurology. He is also Professor of Psychiatry at University of California San Diego.

Dr. Kalali is active in facilitating scientific collaboration between academia, government, and pharmaceutical industry scientists. He was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), and currently the Executive Secretary. He is also active in the International Society for CNS Clinical Trials and Methodology (ISCTM), where he is a member of the Executive Committee and the Scientific Committee, and chairs the Publication Committee. He has also been involved in the effort which resulted in the launch of the CNS Summit in 2010.

Dr. Kalali has been an academic investigator in over 70 psychopharmacological clinical trials and at Quintiles has had medical and scientific responsibility for over 300 clinical trials. He is an expert in CNS clinical trial methodology, including clinical rating scales, and has trained investigators from over forty countries. Dr. Kalali is the Editor of the
journal Innovations in Clinical Neuroscience, and is on the editorial board of several other journals. He has published widely in journals such as the Archives of General Psychiatry, The American Journal of Psychiatry, and the British Journal of Psychiatry.

Dr. Kalali is an active member of many professional societies including the American College of Neuropsychopharmacology, the American Society for Clinical Psychopharmacology, the American Psychiatric Association, the Canadian College of NeuroPsychopharmacology, the Collegium Internationale Neuro Psychopharmacologicum, the Drug Information Association, the International Society for CNS Drug Development, the International Society for CNS Clinical Trials and Methodology, the Royal College of Psychiatrists, United Kingdom, and the Society for Neuroscience.


Terence Ketter, MD
Chief, Stanford University Bipolar Disorders Clinic and Professor of Psychiatry and Behavioral Sciences
Stanford University, Palo Alto, CA

Terence Ketter received his medical degree from the University of Toronto, completed internship and residency training at the University of California San Francisco, and fellowship training in psychopharmacology and brain imaging and at the National Institute of Mental Health in Bethesda. He is Chief of the Stanford University Bipolar Disorders Clinic and Professor of Psychiatry and Behavioral Sciences. Dr. Ketter’s research interests include the use of brain imaging methods such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) to better understand the neurobiology of mood disorders and to explore the possibility of using these techniques to more effectively target treatments for patients with bipolar disorders. Dr. Ketter has also done research in the use of novel medications and combinations of medications in the treatment of bipolar disorders, with an emphasis on the use of anticonvulsants and second generation antipsychotics and the comparative effectiveness of different pharmacotherapies. Recently his research group's work has revealed new insights into the links between creativity, temperament, and mood disorders. His research in these areas has been published extensively. He has published over 300 scientific articles and book chapters and is the editor of the books “Advances in the Treatment of Bipolar Disorder” and “Handbook of Diagnosis and Treatment of Bipolar Disorder”.


Amy M. Kilbourne, PhD, MPH
Associate Professor of Psychiatry, University of Michigan
Associate Director, VA National Serious Mental Illness Treatment
Resource and Evaluation Center, Ann Arbor, MI
Dr. Kilbourne’s research is focused in three primary areas: 1) implementation of behavioral interventions for bipolar and other mental disorders, 2) integrated mental health and medical care models; and 3) application of large outcomes databases to inform mental health policy and practice. Her goal is to improve quality and outcomes of care for persons with mental disorders, and she has been widely recognized for her work in implementation science, integrated mental health and primary care, and preventable mortality in mental health. Notably, Dr. Kilbourne has implemented Life Goals Collaborative Care, a program combining best practices in chronic care management and behavioral change for persons with bipolar and other mental disorders. She has also adapted a groundbreaking implementation model (Replicating Effective Programs) to facilitate the uptake of evidence-based programs in community-based settings. She has several national grants and over 100 peer-reviewed scientific articles, and serves on several national committees including the National Network of Depression Centers Interventions Dissemination Workgroup and the VA Mental Health Quality Enhancement Research Initiative. She is sought out for her expertise in implementation methods, evidence-based psychosocial and behavioral interventions, and application of large outcomes databases to understand and reduce preventable mortality in mental disorders throughout the United States and internationally. She also regularly consults with decision makers at community-based practices on implementing interventions to integrate care and improve quality for persons with mental disorders. After receiving her MPH in epidemiology and PhD health services from the University of California, Los Angeles, Dr. Kilbourne joined RAND Health (Santa Monica, CA), and was then appointed Assistant Professor of Medicine and Psychiatry at the University of Pittsburgh in 1999.


Fouzia Laghrissi-Thode, MD
Head of Global Product Strategy for Metabolism and Anaemia
F. Hoffmann-La Roche, Basel, Switzerland

Fouzia Laghrissi-Thode, M.D., is Head of Global Product Strategy for Metabolism and Anaemia at F. Hoffmann-La Roche., based in Basel, Switzerland. She joined Roche in 2000 as a CNS Leader in the New Medicines Strategy Marketing Department and in 2001 was appointed CNS Business Development Director in Pharma Partnering. In 2003 her responsibilities were extended to leading the business development Primary Care activities including CNS, Cardiovascular and Genito-Urinary disease areas. She was appointed Lifecycle Leader for dalcetrapib for cardiovascular diseases in 2006 and lead the dal-HEART program with more than 15 000 patients.

Prior to joining Roche, Dr. Laghrissi-Thode was a CNS Senior Clinical Research Physician at Novartis Pharma in Basel. She holds an appointment as an Adjunct Professor of Psychiatry at the University of Pittsburgh School of Medicine, USA. As a Principal Investigator she conducted a number of studies in depressed elderly and medically ill patients, and actively participated as co-investigator in the research conducted by the NIMH CRC for the Study of Affective Disorders and Late Life Mood Disorders. Her research was recognized by the N.I.M.H. and the American Federation of Aging Research Award (AFAR).

After graduating in Medicine at the University of Tours, France, in 1987, she specialized in Psychiatry and received her European board certification in 1992.


Marion Leboyer, MD, PhD
Professor of Psychiatry, University of Paris
Department of Psychiatry and Psychiatry Genetic Lab, INSERM
Paris, FRANCE

Marion Leboyer, MD, PhD is Professor of Psychiatry at the University of Paris and also serves as the head of the university-affiliated Department of Psychiatry at the Hospital Chenevier-Mondor in France. Dr. Leboyer is also the Director of the Psychiatry Genetics Laboratory for the French National Institute of Health and Medical Research (INSERM).

Dr. Leboyer also serves as the Director of FondaMental, a foundation created by the French Ministry of Research aiming at creating a network of expert centers and promoting research in Psychiatry. FondaMental’s core objectives focus on better detection and diagnosis of psychiatric disorders; improving the understanding of their causes; training; and more effective communication strategies for addressing the stigma of mental health disorders. The organization is currently focusing on the most severe psychiatric disorders: bipolar disorder; schizophrenia; autism (particularly high functioning autism); suicide; and depression. Dr. Leboyer’s research efforts have contributed to a better identification of relevant phenotypes for genetic studies, particularly in the field of bipolar disorder, schizophrenia, suicide, autism, OCD and pharmaco-genetic studies.

Dr. Leboyer is a dedicated translational research scientist who has formed productive collaborative relationships with colleagues around the world. As the Principal Investigator of national and international studies, she has been able to produce prominent findings such as the identification in autism of the first mutations in neuroligins (NLGN-3 and NLGN-4). Dr. Leboyer has disseminated her work through a publication portfolio of more than 200 scientific articles and book chapters, as well as 5 books, and is a popular lecturer at conferences and professional meetings throughout the world.


Andrew C. Leon, PhD
Professor of Biostatistics in Psychiatry, Professor of Public Health and DeWitt Wallace Senior Scholar
Weill Cornell Medical College, White Plains, New York

Andrew C. Leon, Ph.D. is Professor of Biostatistics in Psychiatry, Professor of Public Health and a DeWitt Wallace Senior Scholar at Weill Cornell Medical College. His ongoing NIMH-funded research has developed and evaluated statistical techniques for treatment effectiveness analyses in longitudinal, observational studies. He is also examining methods of accounting for the problem of nonequivalent comparison groups in cluster randomized controlled clinical trials. He served as a member of the Psychopharmacologic Drugs Advisory Committee of the US Food and Drug Administration from 2002-2007 and testified before the US Congress, Committee on Veterans Affairs hearing Exploring the Relationship between Medication and Veteran Suicide in February, 2010. Dr. Leon is a member of the Executive Committee of the International Society of CNS Clinical Trails and Methodology (ISCTM) and served as Chair of the ISCTM Scientific Program Committee from 2009-2011. He has published over 200 articles in the fields of biostatistics, research methodology, and clinical psychiatry. He is an Associate Editor of Statistics in Medicine and on the Editorial Board of Journal of Clinical Psychiatry.


David A. Lewis, MD
Professor in Translational Neuroscience and Chairman
Department of Psychiatry, University of Pittsburgh
Director of the Translational Neuroscience Program
Medical Director and Director of Research, Western Psychiatric Institute and Clinic, Pittsburgh, PA

Dr. Lewis is the UPMC Endowed Professor in Translational Neuroscience and Chairman, Department of Psychiatry, University of Pittsburgh; Director of the Translational Neuroscience Program; and Medical Director and Director of Research, Western Psychiatric Institute and Clinic. He also serves as Director of an NIMH Conte Center for the Neuroscience of Mental Disorders, which is focused on understanding the role of prefrontal cortical dysfunction in the pathophysiology of schizophrenia. He received his medical degree from the Ohio State University, completed residencies in internal medicine and in psychiatry at the University of Iowa, and received his research training at the Research Institute of the Scripps Clinic. Dr. Lewis has published over 350 scientific articles. He has received NIMH Senior Scientist and MERIT Awards, a Distinguished Investigator Award from NARSAD and is a Fellow in the American College of Neuropsychopharmacology and in the American College of Psychiatrists. He is a member of the Institute of Medicine of the National Academy of Sciences and serves on the National Advisory Mental Health Council. He is also a Deputy Editor of The American Journal of Psychiatry and of Neurobiology of Disease. Recognition of Dr. Lewis’ research accomplishments has included the Lieber Prize for Schizophrenia Research from NARSAD, the William K. Warren Award from the International Congress of Schizophrenia Research, the Stanley Dean Research Award from the American College of Psychiatrists, and the APIRE/Kempf award for mentorship from the American Psychiatric Association.

Dr. Lewis’ research activities focus on the neural circuitry of the prefrontal cortex and related brain regions, and the alterations of this circuitry in schizophrenia. The research strategy underlying these investigations involves several components. First, the normal functional architecture of the prefrontal cortex, including its connections with other cortical and subcortical regions, is examined using the macaque monkey as a model system for the human brain. Within these circuits, the expression and cellular localization of specific gene products, and how these change in an activity-dependent fashion, are investigated. The electrophysiological properties of intrinsic prefrontal cortical circuits are studied using an in vitro slice preparation. Second, the postnatal development of prefrontal cortical circuitry is characterized, with special emphasis placed on maturational events, such as synaptogenesis and synaptic pruning, which occur during early postnatal life and adolescence. The timing and specificity of these processes are examined for their possible contribution to the emergence and refinement of the types of cognitive abilities that are disturbed in schizophrenia. Third, based on the results of these lines of investigation, hypotheses are generated regarding the elements of neural circuitry that may be dysfunctional in schizophrenia. These hypotheses are then tested in postmortem human brain specimens from subjects with schizophrenia. Fourth, the primate model system is used to assess the influence of psychotropic medications on the neural circuits of interest, and mouse genetic models are used as “proof of concept” tests of the cause-effect relationships between the alterations observed in the disease state. The goal of these studies is to define the pathogenetic mechanisms and pathophysiological processes that give rise to the cognitive deficits of schizophrenia. Finally, these findings are used to identify potential targets for novel therapeutic interventions that are examined in Phase II clinical trials.


Gin S. Malhi, MD, FRCPsych, FRANZCP
Chair, Discipline of Psychiatry, Sydney Medical School, University of Sydney
Director, CADE Clinic, Royal North Shore Hospital, Sydney, Australia

Professor Gin Malhi is the Head of the Discipline of Psychiatry at Sydney University. He is also the clinical director of the CADE Clinic research unit (www.cadeclinic.com) and in addition to conducting clinical research he teaches medical students at Sydney Medical School and registrars at Royal North Shore Hospital. He has a longstanding interest in mood disorders particularly bipolar disorder and depression, and in recent years has increasingly used clinical and neuropsychological assessments in conjunction with neurobiological probes, to investigate the neural basis of affective disorders. He has published more than 250 papers and is currently Editor of The Australian and New Zealand Journal of Psychiatry.


Husseini K. Manji, MD, FRCPC
Visiting Professor, Duke University, Durham, North Carolina
Global Therapeutic Head, Neuroscience
Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ

Husseini K. Manji, MD is Global Therapeutic Head, Neuroscience, Johnson and Johnson Pharmaceutical Research and Development. He was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following residency training, he completed fellowship training at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK. The major focus of his research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics. Dr. Manji is a previous recipient of numerous research awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished research, the Canadian Association of Professors Award, the Brown University School of Medicine Distinguished Researcher Award, the DBSA Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction, and the NIMH award for excellence in clinical care and research.

In addition to his neuroscience research, and biomarker and therapeutics development endeavors, Dr. Manji has also been actively involved in medical and neuroscience education undertakings, and has served as a member of the National Board of Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee, and numerous national curriculum committees. He has developed and co-directed the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Neuropsychiatric Illness, has received both the NIMH Mentor of the year and NIMH Supervisor of the year awards, and the Henry and Page Laughlin Distinguished Teacher Award. He has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. He has been editor of Neuropsychopharmacology Reviews: the next generation of progress, deputy editor of Biological Psychiatry, associate editor of the journal Bipolar Disorders, and sits on the editorial board of numerous journals. Dr. Manji has been inducted into the National Academy of Sciences’ Institute of Medicine (IOM), is a Councilor of both the ACNP and Society of Biological Psychiatry, co-chairs the NIH Biomarkers Neuroscience Steering Committee, chaired the ACNP’s Task Force on New Medication Development, and is immediate past president of the Society of Biological Psychiatry.


David J. Miklowitz, PhD
Professor Psychiatry, Director, UCLA Child and Adolescent Mood Disorders Program
Director, Integrative Study Center in Mood Disorders
UCLA Semel Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA
Senior Clinical Researcher, Department of Psychiatry, Warneford Hospital, Oxford University, Oxford, UK

Dr. Miklowitz is Professor of Psychiatry in the Division of Child and Adolescent Psychiatry at the UCLA Semel Institute, and a Senior Clinical Research Fellow in the Department of Psychiatry at Oxford University. He completed his undergraduate work at Brandeis University and his doctoral (1979-1985) and postdoctoral (1985-1988) work at UCLA. His research focuses on family environmental factors and family psychoeducational treatments for adult-onset and childhood-onset bipolar disorder.

Dr. Miklowitz received the Joseph Gengerelli Dissertation Award from UCLA (1986), Young Investigator Awards from the International Congress on Schizophrenia Research (1987) and the National Alliance for Research on Schizophrenia and Depression (NARSAD; 1987), a Faculty Research Award (1998) and a Faculty Teaching Award (2008) from the University of Colorado, and a Distinguished Investigator Award from NARSAD (2001). He won the 2005 Mogens Schou Award for Research from the International Society for Bipolar Disorders and the 2008 Clinical Researcher of the Year award from Emory University. He also won the 2009 Gerald L. Klerman Senior Research Investigator Award from the Depressive and Bipolar Support Alliance. He has received funding for his research from the National Institute of Mental Health, the John D. and Catherine T. MacArthur Foundation, the Robert Sutherland Foundation, and the Danny Alberts Foundation.

Dr. Miklowitz has published 225 research articles and book chapters on bipolar disorder and schizophrenia, and six books. His articles have appeared in the Archives of General Psychiatry, the American Journal of Psychiatry, the British Journal of Psychiatry, the Journal of Nervous and Mental Disease, Biological Psychiatry, the Journal of Consulting and Clinical Psychology, and the Journal of Abnormal Psychology. His book with Michael Goldstein, Bipolar Disorder: A Family-Focused Treatment Approach (Guilford), won the 1998 Outstanding Research Publication Award from the American Association for Marital and Family Therapy. His book “The Bipolar Disorder Survival Guide” has sold over 200,000 copies, and is now out in a second edition. His latest book, co-edited with Dante Cicchetti, is titled "Understanding Bipolar Disorder: A Developmental Psychopathology Perspective."


Andrew A. Nierenberg, MD
Professor of Psychiatry, Harvard Medical School
Director of the Bipolar Research Program, Associate Director, Depression Clinical and Research Program
Massachusetts General Hospital (MGH), Boston, MA

Dr. Nierenberg is Professor of Psychiatry, Harvard Medical School, Director of the Bipolar Research Program, and Associate Director of the Depression Clinical and Research Program, Massachusetts General Hospital (MGH). He attended the Albert Einstein College of Medicine of Yeshiva University followed by a residency in psychiatry at New York University/Bellevue Hospital and then became a Robert Wood Johnson Clinical Scholar at Yale University. Dr. Nierenberg then ran one of the Affective Disorders Inpatient Units and the Affective Disorders Outpatient Unit at McLean Hospital in Belmont, MA. In 1992, he joined the Psychiatry Department at MGH.

He has published over 250 original articles and over 60 reviews, editorials, and chapters, and has been listed among the Best Doctors in North America for the treatment of mood and anxiety disorders continuously since 1994. He received the NDMDA Gerald L. Klerman Young Investigator Award and was elected as a member of the American College of Neuropsychopharmacology (ACNP) and as a Distinguished Fellow of the American Psychiatric Association.

Dr. Nierenberg is the Director of the NIMH Bipolar Trials Network which is currently conducting CHOICE, 10-site nationwide comparative effectiveness trial of lithium and quetiapine. Additionally, the Bipolar Trials Network is in the final stages of completing LiTMUS, an effectiveness trial of low dose lithium alone or in combination with optimized treatment. His primary interests are treatment resistant depression, bipolar depression, and the longitudinal course of mood disorders. Dr. Nierenberg lectures nationally and internationally, teaches and supervises clinicians and researchers, maintains an active clinical practice, conducts clinical trials, and is Editor in Chief of CNS Spectrums as well as on the editorial boards of multiple psychiatric journals.


Dost Ongür, MD, PhD
Assistant Professor of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA

Dost Ongur, MD, PhD joined the faculty of Harvard Medical School in July, 2004 after completing his psychiatry residency at the MGH/McLean training program. Dr. Ongur’s research focuses on magnetic resonance spectroscopy studies of glutamatergic and GABAergic abnormalities in bipolar disorder and schizophrenia. A 2000 graduate of the Washington University in St. Louis School of Medicine, Dr. Ongur currently is the Clinical Director of the Psychotic Disorders Division at McLean Hospital and has a Career Development Award from NIMH. Dr. Ongur has been elected to Associate membership of the American College of Neuropsychopharmacology and has authored or co-authored more than 50 scientific articles and book chapters.


Michael J. Ostacher, MD, MPH
Assistant Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Associate Director, VA/Stanford Bipolar Research Program, VA Palo Alto Health Care System

After graduating with Honors in the College of Letters at Wesleyan University in Connecticut, Dr. Ostacher received his medical degree from the Vanderbilt University School of Medicine in Nashville, Tennessee. He trained in Adult Psychiatry at Harvard Medical School at The Cambridge Hospital, and completed fellowships in Public Psychiatry and Geriatric Psychiatry there. He completed a Masters in Public Health in Health Care Management at the Harvard University School of Public Health, and received a Masters in Medical Sciences as part of the Scholars in Clinic Science Program at Harvard Medical School.

Dr. Ostacher's major research interest is bipolar disorder and comorbid substance abuse, and received a Career Development Award from the National Institute on Alcoholism and Alcohol Abuse (NIAAA) to study substance abuse and mood while the Associate Medical Director of the Bipolar Clinic and Research Program at Massachusetts General Hospital. Dr. Ostacher won National Association for Research in Schizophrenia and Depression (NARSAD) Young Investigator Awards in 2005 and 2009 to study cognition in patients with bipolar disorder and substance abuse, and received a New Investigator Award in 2004 from the National Institute of Mental Health (NIMH), and is faculty for the University of Pittsburgh/NIMH Bipolar Career Development Institute. He was the principal investigator at MGH for BALANCE, a multinational study of maintenance treatments for bipolar disorder at Oxford University in the United Kingdom, and was the Site PI for the NIMH Bipolar Trials Network at MGH. Since August 2010, he has been on the faculty in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, working alongside Dr. Trisha Suppes.


Mary L. Phillips, MD
Professor in Clinical and Translational Science
Head, Clinical and Translational Affective Neuroscience Program
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA

Dr. Mary Phillips trained in Medicine at the University of Cambridge, UK and in Psychiatry at the Maudsley Hospital, London and Institute of Psychiatry, UK. She received a research training fellowship from the Medical Research Council (UK) to examine visual scan paths in schizophrenia. She subsequently developed a research interest in the application of functional neuroimaging techniques to the examination of the neural basis of emotion processing in healthy and psychiatric populations. She has, in particular, focused on the identification of neural correlates that underlie the symptoms of specific abnormalities in emotion processing in individuals with mood disorders. She became Professor of Neuroscience and Emotion and Head of Section of Neuroscience and Emotion within the Department of Psychiatry, Division of Psychological Medicine, Institute of Psychiatry, King’s College, London, UK in 2003. In October, 2004, she joined the Department of Psychiatry at the University of Pittsburgh as part-time Visiting Professor and Director of the Functional Neuroimaging Program, moving to become a Professor of Psychiatry in April, 2006. In 2005, Dr. Phillips became a member of The American College of Neuropsychopharmacology, and in 2006, was awarded the Nellie Blumenthal Investigator by the National Alliance for Research in Schizophrenia and Depression. Since 2006, Dr. Phillips has been Co-Director of the Brain Imaging Research Center within Carnegie Mellon University and the University of Pittsburgh. In January, 2008, Dr. Phillips took up a consulting adjunct position of Professor in Clinical Affective Neuroscience in the Department of Psychological Medicine, Cardiff University, UK. In 2009, Dr. Phillips became Professor in Clinical and Translational Science in the University of Pittsburgh, and now heads the Clinical and Translational Affective Neuroscience Program in the Department of Psychiatry, University of Pittsburgh. Dr Phillips has received research funding awards from the Medical Research Council (UK) and the Wellcome Trust in the UK, and, from NIMH and NARSAD in the US. Dr. Phillips is a mentor to over 30 junior investigators, has extensive national and international collaborations, and has authored or co-authored over 170 publications.


Noreen A. Reilly-Harrington, PhD
Director of Training and Assessment, Bipolar Trials Network
Massachusetts General Hospital & Harvard Medical School, Boston, MA
Noreen Reilly-Harrington, Ph.D. is a Founding Fellow of the Academy of Cognitive Therapy and specializes in the cognitive-behavioral treatment of bipolar disorder. She has co-authored several books and numerous manuscripts on this topic. She is a graduate of the University of Pennsylvania and Temple University and completed both her pre-doctoral internship and post-doctoral fellowship in cognitive-behavioral therapy at Massachusetts General Hospital and Harvard Medical School. Dr. Reilly-Harrington served as the Clinical and Scientific Coordinator of the Psychosocial Pathway in the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), the largest study of bipolar disorder ever conducted. She has also been the Principal Investigator on two NIMH-sponsored Small Business Innovative Research projects geared at improving the design and reliability of multi-site psychiatric assessment and research. Currently, Dr. Reilly-Harrington serves as the Director of Training and Assessment for the Bipolar Trials Network and advises the multi-site network on protocol design, assessment selection, and training. Dr. Reilly-Harrington is also actively involved in the teaching and provision of cognitive-behavioral treatment at the Massachusetts General Hospital Bipolar Clinic and Research Program and is on the faculty of Harvard Medical School. She also serves as an affiliated faculty member for the Career Development Institute for Bipolar Disorder.


Martha Sajatovic, MD
Professor of Psychiatry, Case Western Reserve University School of Medicine in Cleveland, Ohio

Dr. Sajatovic is Professor of Psychiatry at Case Western Reserve University School of Medicine in Cleveland, Ohio. She is a researcher, educator, and clinician who has devoted herself to the study and treatment of traditionally hard-to treat populations with serious mental illness. Dr. Sajatovic is Director of Geropsychiatry at University Hospitals Case Medical Center (UHCMC) and holds the Willard Brown Chair in Neurological Outcomes at UHCMC/Case Western Reserve University School of Medicine.

Dr. Sajatovic’s research interests have focused on illness outcomes in serious mental illness such as bipolar disorder and schizophrenia. Dr. Sajatovic is a recognized expert in the areas of treatment adherence in bipolar disorder and in late-life bipolar disorder. She also has research interests in the psychopharmacology of psychosis and serious mood disorders, and in mental health rating scales. Over the last two decades, Dr. Sajatovic has been the recipient of multiple research grants to study serious mental illness including support from the National Institute of Mental Health (NIMH), the National Institute of Aging (NIA), the Ohio Department of Mental Health (ODMH), the Veterans Health Administration (VHA), a variety of Mental Health Foundations, and Industry Sponsored clinical trials.

Dr. Sajatovic has published widely on treatments and health services delivery among individuals with serious mental illness including geriatric and mixed-age individuals with bipolar disorder, schizophrenia, depression and post-traumatic stress disorder as well as in the area of treatment adherence in bipolar disorder. She has authored or co-authored over 100 peer-reviewed publications, and has published over 30 book chapters or books on serious mental illness topics.

Dr. Sajatovic has been a guest lecturer at numerous academic and community settings, both on a national and international level, including speaking to consumer and family advocacy groups for individuals with psychiatric illness. Dr. Sajatovic has been a recipient of the Exemplary Psychiatrist Award bestowed by the National Alliance for the Mentally Ill (NAMI), and was a Depression and Bipolar Support Alliance (DBSA) 2006 Gerald Klerman Young Investigator Award winner.


Etienne Sibille, PhD
Associate Professor of Psychiatry, University of Pittsburgh, Pittsburgh, PA

Etienne Sibille, Ph.D., joined the faculty of the University of Pittsburgh in 2004, after training in molecular neuropsychiatry at Cornell and Columbia Universities. His research goals have consistently focused on translational research aimed at identifying the cellular and molecular bases of depression, and specifically of the mood and affect dysregulation component of the illness. Studies in the Sibille laboratory encompass parallel investigations in postmortem brains of depressed and control subjects, and in rodent genetic and environmental models. The scientific goals are to characterize the primary pathology of depression and to assess causality relationships between identified molecular changes or candidate neurotransmitter systems and mood regulation.
In addition, Dr. Sibille’s laboratory has demonstrated that biological pathways affected during aging of the human brain largely overlap with neuropsychiatric and other neurological disease pathways and may in fact promote diseases, together providing a compelling rationale for investigating aging and diseases simultaneously. These latter hypotheses are now being tested in parallel in the human postmortem brain and in large epidemiological studies of subjects at the vigor-to-frailty transition.

Dr. Sibille has been elected to the membership of the American College of Neuropsychopharmacology and has authored more than 40 scientific research articles. He is the recipient of several NIMH grants and of a NIMH Independent Scientist Award.


Maria Silva
Family Support Partner Supervisor/Coach, High Fidelity Wraparound Program
Children Youth and Families (CYF) and Gwen’s Girls Initiatives, Pittsburgh, PA

Maria Silva is a Supervisor and Credentialed Coach at Allegheny Family Network – specializing in High Fidelity Wrap Around. Since 1996, Ms. Silva has provided peer-to-peer crisis and emotional support to parents raising children with mental health issues, cognitive disabilities, behavioral concerns, and educational issues in various roles and positions. Ms. Silva formed and served as president of the Pennsylvania Prader-Willi Syndrome Association where her chapter has offered trainings, conferences, and support to other families raising children with Prader-Willi Syndrome. She serves on the National Prader-Willi Peer-to-Peer Support Network. Ms. Silva has raised six children, three of whom have various mental health challenges. Through her professional career and personal calling, Ms. Silva continues to offer hope and leadership to families as they journey towards acceptance, resiliency, and self-advocacy.


Stephen M. Strakowski, MD
Professor and Chairman, University of Cincinnati College of Medicine, Cincinnati, Ohio

Stephen M. Strakowski, MD, is the Dr. Stanley and Mickey Kaplan Professor and Chairman of Psychiatry at the University of Cincinnati College of Medicine, and the Chief of Psychiatry at University Hospital. He is also the Director of the Center for Imaging Research, a core human research MRI center for the University and the Brain Imaging Center at the Lindner Center of HOPE, a University affiliate. He also serves as the Director of Research for University of Cincinnati Physicians. Finally, he is also Professor of Psychology and Biomedical Engineering at UC. Dr. Strakowski graduated summa cum laude from the University of Notre Dame with a BSE in 1984 and alpha omega alpha from Vanderbilt University School of Medicine with an MD in 1988. He completed his residency training at McLean Hospital/Harvard University School of Medicine in 1992. Upon completing residency, he moved to the University of Cincinnati as an Assistant Professor, where he has remained and has been promoted to his current positions. Dr. Strakowski has received numerous awards and has been named among the Best Doctors in America for many years. He has over 200 peer-reviewed publications and over 300 chapters, published abstracts, and solicited reviews. He serves on several editorial boards and is the Field Editor for Neuroimaging for Bipolar Disorders.


Trisha Suppes, MD, PhD
Director, Bipolar Disorder Research Program, VA Palo Alto Health Care System, Palo Alto, CA
Professor, Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine, Stanford, CA

Trisha Suppes, M.D., Ph.D. joined the faculty of Stanford University and the VA Palo Alto as Professor of Psychiatry and Behavioral Sciences in 2008, following more than fifteen years at the University of Texas Southwestern Medical Center. Her areas of expertise and research include long-term treatment strategies for bipolar disorder, treatment for bipolar II disorder, development and implementation of treatment algorithms, treatment of bipolar depression and use of complementary medicine for bipolar disorder. A 1987 graduate of Dartmouth Medical School, Dr. Suppes was a member of the American Psychiatric Association (APA) Work Group for the Practice Guidelines for Bipolar Disorder, was chair for the Veterans Affairs, DoD and VA Bipolar Disorder Treatment Guidelines, and is currently a member the Mood Disorder Workgroup for the development of the Diagnostic and Statistical Manual for Mental Disorders, version 5 (DSM-5). Additionally, Dr. Suppes is a Distinguished Fellow with the American Psychiatric Association, a Fellow with the American College of Neuropsychopharmacology, a member of the Board of Councilors for the International Society for Bipolar Disorders, an associate editor for the American Journal of Psychiatry and a member of the Scientific Advisory Board of the Depression and Bipolar Support Alliance. She has authored or co-authored over 185 peer-reviewed articles.


Holly A. Swartz, MD
Associate Professor of Psychiatry, University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Dr. Swartz received a bachelor’s degree from Harvard University in Cambridge, Massachusetts and her medical degree from the Albert Einstein College of Medicine in the Bronx, New York. She completed her psychiatric residency at Payne Whitney Clinic-New York Hospital in New York City, and she joined the faculty of the Department of Psychiatry at the University of Pittsburgh Medical School in 1997. She is currently an attending psychiatrist at the Depression and Manic-Depression Prevention Program of Western Psychiatric Institute and Clinic.
Dr. Swartz’s research is supported by the National Institute of Mental Health (NIMH) and focuses on the development and evaluation of psychosocial interventions for the treatment of mood disorders. She is currently evaluating the roles of psychotherapy and pharmacotherapy in the management of bipolar ll disorder. She is also evaluating the impact of maternal depression treatment on offspring with psychiatric disorders. She is the recipient of several research awards including a 2003 NCDEU New Investigator Award, the 2005 Gerald L. Klerman Young Investigator Award from the Depression and Bipolar Support Alliance, and the 2009 Klerman Interpersonal Psychotherapy Award from the International Society for Interpersonal Psychotherapy. She has authored or co-authored over 60 scientific papers and book chapters. Dr. Swartz has presented her work at numerous local, national, and international workshops, conferences and scientific meetings.


Mauricio Tohen, MD, DrPH, MBA
Head of the Division of Mood and Anxiety Disorders
Aaron and Bobbie Eliott Krus Chair Endowed Professor in Psychiatry
University of Texas Health Science Center at San Antonio, TX

Dr. Mauricio Tohen graduated as a doctor of medicine from the National University of Mexico and as a doctor of public health (epidemiology) from Harvard University. His postdoctoral training included a residency in psychiatry at the University of Toronto and a fellowship at McLean Hospital, Harvard Medical School. He also obtained an MBA degree from Indiana University Kelly School of Business.
From 1988 to 1997, he was clinical director of the Bipolar and Psychotic Disorder Program at McLean Hospital. From 1997 to 2008 he worked at Lilly Research Laboratories attaining the highest possible scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as Head of the Division of Mood and Anxiety Disorders and the Aaron and Bobbie Eliott Krus Chair Endowed Professor in Psychiatry

He received a National Service Award in Psychiatric Epidemiology from NIMH and Harvard University. He also received a FIRST award from NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award. Dr. Tohen's research, supported by grants from NIMH and the pharmaceutical industry, has focused on the epidemiology, outcome, and treatment of bipolar disorder.
In 2011 Dr. Tohen received the Simon Bolivar Award from the American Psychiatric Association. He has served on the Council on Research and the committee on Health Services Research of the American Psychiatric Association. He has also served in the Epidemiology & Genetics and the Clinical Centers and Special Projects Review committees at NIMH. Dr. Tohen has over 200 publications. He has co-edited four books, Psychiatric Epidemiology (1995, second edition 2003), Mood Disorders Across the Life Span (1996) ). Bipolar Disorder: The Upswing In Research and Treatment (2005) and Bipolar Psychopharmacotherapy (2006). He also edited the book Comorbidity in Affective Disorders (1999).


Bryan K. Tolliver, MD, PhD
Assistant Professor of Psychiatry, Medical University of South Carolina, Charleston, SC

Bryan K. Tolliver, M.D., Ph.D. is an Assistant Professor in the Clinical Neuroscience Division of the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. His primary clinical and research interest is in the treatment of co-occurring bipolar disorder and substance use disorders. After undergraduate training at the University of North Carolina at Chapel Hill, Dr. Tolliver received a Ph.D. from the Department of Pharmacology at the University of Kentucky in 1994 and completed a postdoctoral fellowship in preclinical addiction research training at the University of California, San Francisco from 1994-1999. After receiving his medical degree from the University of Kentucky College of Medicine in 2003, he completed psychiatry residency in 2007 and addiction psychiatry fellowship training in 2008, both at the Medical University of South Carolina. Dr. Tolliver has received fellowship and grant support from the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). He is currently funded by NIAAA to investigate medication treatment effects on drinking, mood, and neurocognitive outcomes in individuals with co-occurring bipolar disorder and alcohol dependence. Dr. Tolliver presently serves on the Evidence-Based Treatment Committee of the American Academy of Addiction Psychiatry and on the Research Committee of the International Society for Bipolar Disorders.


Eduard Vieta, MD, PhD
Professor of Psychiatry, University of Barcelona
Director, Bipolar Disorders Program, Hospital Clinic, Barcelona, Spain

Eduard Vieta is Professor of Psychiatry and the Director of the Bipolar Disorders Program of the Hospital Clinic at the University of Barcelona, in Barcelona, Spain. His research focuses on the neurobiology, epidemiology, and treatment of bipolar disorder. He is the current Director of the Bipolar Research Program at the Centro de Investigación en Red de Salud Mental (CIBERSAM), funded by the Spanish Ministry of Science and Innovation and one of the leaders of the European Network on Bipolar Expert Centers (ENBREC). He has also been nominated the official advisor on mood disorders research for the EU Presidency (Hungarian Government) and sits in the Executive Committee of the European College of Neuropsychopharmacology (ECNP). He has made significant contributions to many of the current bipolar disorder treatment guidelines, and with an H index of 46, has authored more than 400 original articles in peer-reviewed, top-ranking journals, 160 book chapters and 28 complete books. He is the most cited psychiatrist in Spain and sits on the editorial board of 18 international scientific journals and reviews articles for more than 30 others. He recently received the Aristotle Award and the Mogens Schou Award for excellence in bipolar disorder research.


Adele C. Viguera, MD, MPH
Director of Mental Health Outcomes Research, Neurological Institute, Cleveland Clinic
Co-director of the National Pregnancy Registry for Atypical Antipsychotics
Massachusetts General Hospital, Boston, MA
Assistant Professor of Psychiatry at the Cleveland Clinic Lerner College of Medicine
Cleveland Clinic, Cleveland, Ohio

Dr. Adele C. Viguera, M.D., M.P.H., currently serves as co-director of the National Pregnancy Registry for Atypical Antipsychotics and holds a joint appointment at the Cleveland Clinic and Massachusetts General Hospital. She is an Assistant Professor of Psychiatry at the Cleveland Clinic Lerner College of Medicine.
Dr. Viguera received her undergraduate degree from Harvard University, her medical degree from Dartmouth Medical School, and her Masters Degree in Epidemiology from the Harvard School of Public Health. She completed her Internship in Medicine from Massachusetts General Hospital, residency training in Psychiatry at McLean Hospital, and a fellowship in Perinatal and Reproductive Psychiatry at Massachusetts General Hospital. She has also served as the Associate Director of the Perinatal and Reproductive Psychiatry Clinical Research Program at Massachusetts General Hospital since 1997.

Dr. Viguera’s research, teaching and clinical activities focus on women’s mental health, specifically psychiatric disorders across the female reproductive life-cycle. Her research area is major mood disorders, in particular bipolar disorder. She is a past recipient of several federal and private foundation research grants including a National Institute of Mental Health (NIMH) Mentored Patient-Oriented Career Development (K23) Award, a Harvard Medical School Scholars in Medicine Award, and a Young Investigator Award from the National Association of Research in Schizophrenia and Depression (NARSAD). She is also an R01 funded principal investigator for a collaborative, multi-site study entitled, Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity, sponsored by the National Institute of Mental Health.

Dr. Viguera has published extensively in the area of area of perinatal and reproductive psychiatry, with several original research articles published in the American Journal of Psychiatry. She has also been an invited speaker at numerous international and national conferences, and served on the expert consensus panel, convened under the aegis of the American Psychiatric Association, for the publication of guidelines on the management of bipolar disorder during pregnancy and the postpartum period. In addition to these research efforts, Dr. Viguera continues to dedicate her time to teaching and mentoring psychiatric residents, fellows, medical students, and junior faculty.


Nora D. Volkow, MD
Director, National Institute on Drug Abuse, National Institutes of Health, Rockville, MD

Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction.

Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging.

Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA.

Dr. Volkow spent most of her professional career at the Department of Energy’s Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

Dr. Volkow has published more than 440 peer-reviewed articles and more than 75 book chapters and non-peer reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders.

During her professional career, Dr. Volkow has been the recipient of multiple awards, including her selection for membership in the Institute of Medicine in the National Academy of Sciences and the International Prize from the French Institute of Health and Medical Research for her pioneering work in brain imaging and addiction science. She was recently named one of Time Magazine's “Top 100 People Who Shape our World” and was included as one of the 20 people to watch by Newsweek magazine in its “Who’s Next in 2007” feature. She was also included in Washingtonian Magazine’s 2009 list of the “100 Most Powerful Women” and named “Innovator of the Year” by U.S. News & World Report in 2000.


Katherine L. Wisner, MD, MS
Professor of Psychiatry, Obstetrics/Gynecology and Reproductive Sciences, Epidemiology and
Women’s Studies, University of Pittsburgh
Director, Women's Behavioral HealthCARE Program
Western Psychiatric Institute and Clinic of the University Pittsburgh Medical Center, Pittsburgh, PA

Katherine L. Wisner M.D., M.S., is Professor of Psychiatry, Obstetrics/Gynecology and Reproductive Sciences, Epidemiology and Women’s Studies at the University of Pittsburgh, and director of the Women's Behavioral HealthCARE program at the Western Psychiatric Institute and Clinic (WPIC) of the University Pittsburgh Medical Center. She also serves as an investigator at the Magee-Womens Research Institute. Dr. Wisner obtained an M.S. in Nutrition and her M.D. from Case Western Reserve University, followed by a categorical pediatric internship and general and child psychiatry residency at Children’s Hospital of Pittsburgh and WPIC. She completed as a post-doctoral fellow in Epidemiology at the University of Pittsburgh Graduate School of Public Health from 1985-1988 and a fellowship in Professional Ethics at Case Western Reserve University in 1996.

Dr. Wisner's main focus is research related to the psychiatric treatment of women of childbearing age. She is recognized as an expert in the treatment of depression during pregnancy and the postpartum period. She currently is the principal investigator on several National Institute of Mental Health and foundation-funded research projects including a large-scale postpartum depression screening at Magee Womens Hospital, the use of antidepressant and antimanic agents during pregnancy, novel treatments for postpartum depression, the efficacy of bright light treatment for patients with bipolar disorder and mental health treatment delivery within community settings.

Dr. Wisner is board-certified in general, child and adolescent psychiatry. Her memberships in scientific societies include the Organization of Teratology Information Specialists (Board member), North American Society for Psychosocial Obstetrics and Gynecology, American College of Neuropsychopharmacology (Chair of Human Subjects Committee) and the Marce International Society for the Study of Childbearing-Related Psychiatric Illness (past President). Dr. Wisner is a distinguished fellow of the American Psychiatric Association and was a consultant for the U.S. Centers for Disease Control and Prevention’s Safe Motherhood Initiative, the Agency for Healthcare Research and Quality’s report on Perinatal Depression, and the Food and Drug Administration’s pediatric subcommittee on the effects of maternal SSRI use on newborns. Dr. Wisner completed the prestigious Executive Leadership in Academic Medicine (ELAM) program from Drexel University. She has authored more than 150 peer-reviewed articles and book chapters.

For relaxation, Dr. Wisner has a Morgan horse and trains in dressage.


Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK)
Professor of Psychiatry and Vice Chair for Research and International Affairs
Department of Psychiatry at the University of British Columbia in Vancouver, BC, Canada

Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), is Professor of Psychiatry and Vice Chair for Research and International Affairs in the Department of Psychiatry at the University of British Columbia in Vancouver. His major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham has received a number of awards during his career including the Michael Smith Foundation Senior Scholar Award, Mogen Schou Award for international education and advocacy on bipolar disorder and the Canadian College of Neuropsychopharmacology Medal for his contributions. Dr. Yatham’s work has been funded by a number of peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. Dr. Yatham leads a Canadian consortium on bipolar disorder, which is currently pursuing testing of new treatments for bipolar disorder using pragmatic and controlled trials with substantial funding from CIHR.
Dr. Yatham co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group revised the guidelines for 2005 with International Commentaries. The CANMAT guidelines are widely used for treatment of bipolar disorder around the world as these are updated and published every 2 years in Bipolar Disorders Journal with the most recent update published in May 2009. He is Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. Dr. Yatham was the past President of the International Society for Bipolar Disorders. He sits on the editorial boards of a number of journals including Bipolar Disorders, World Journal of Biological Psychiatry, Human Psychopharmacology, Quarterly Journal of Mental Health etc. He has published over 180 papers in peer-reviewed international journals and presented his research work at numerous international conferences. He has also edited a number of journal supplements and books.


Robert H. Yolken, MD
Ted and Vada Stanley Distinguished Professor of Developmental Neurovirology
Johns Hopkins School of Medicine, Baltimore, MD

Dr Yolken graduated from Harvard Medical School in 1973m completed residency in Pediatrics And Medicine at Yale New Haven Hospital and a Fellowship at New York Hospital. He then received training in the fields of virology and infectious diseases at the National Institutes of Health. He joined the Department of Pediatrics at Johns Hopkins in 1979 and has remained on the faculty of Johns Hopkins since that time. Dr. Yolken initially focused on infections of the gastrointestinal tract. Since 1995 he has focused on infections of the central nervous system particularly as to how they relate to psychiatric disorders such as schizophrenia and bipolar disorder. He is the author of more than 350 publications and many book chapters. He also serves on the boards of the Stanley Medical Research Institute and the March of Dimes.


L. Trevor Young, MD, PhD, FRCPC
Chair, Department of Psychiatry , University of Toronto, Toronto, Ontario, Canada

Dr. Young was appointed Chair, Department of Psychiatry effective September 1, 2010. He received his medical degree at the University of Manitoba. This was followed by residency training at McGill University and the University of Toronto where he also completed his PhD in Medical Sciences. He completed a Research Fellowship at Johns Hopkins University. His former roles include Physician-in-Chief, Executive Vice President Programs at the Centre for Addiction and Mental Health, Professor and Cameron Wilson Chair in Depression Studies in the Department of Psychiatry at the University of Toronto, and Professor and Head, Department of Psychiatry, University of British Columbia. He was received numerous awards including the Douglas Utting Award for outstanding contributions in the field of mood disorders, the Canadian College of Neuropsychopharmacology Heinz Lehmann Award, and is a Distinguished Fellow of the American Psychiatric Association. He has led several large clinical programs including the Mood Disorders Program at Hamilton Psychiatric Hospital, which received the American Psychiatric Services Gold Achievement Award. In 2009, he was elected as a Fellow of the Canadian Academy of Health Sciences.

As an active clinician scientist, Dr. Young’s principal research interest includes understanding the molecular basis of bipolar disorder and its treatment, and how to apply these findings to the clinical setting. He is widely published and well funded by peer-reviewed granting agencies. His research is particularly focused on understanding the processes that lead to long-term changes in brain structure and function in patients with bipolar disorder and how these changes can be targeted by mood stabilizing drugs.


Carlos A. Zarate, MD
Chief, Experimental Therapeutics & Pathophysiology Branch
Section on Neurobiology and Treatment of Mood and Anxiety Disorder
Division Intramural Research Program, National Institute of Mental Health, Bethesda, MD

Carlos A. Zarate, M.D. is Chief, Experimental Therapeutics & Pathophysiology Branch and of the Section on Neurobiology and Treatment of Mood and Anxiety Disorders, Division Intramural Research Program, National Institute of Mental Health. Dr. Zarate completed his residency training in psychiatry at the Massachusetts Mental Health Center/Brockton VAMC division. He later completed a fellowship in Clinical Psychopharmacology at McLean Hospital of the Consolidated Department of Psychiatry, Harvard Medical School and remained on staff at McLean Hospital as the Director of the Bipolar and Psychotic Disorders Outpatient Services and Director of the New and Experimental Clinic. From 1998 to 2000 Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program at the University of Massachusetts Medical School. In 2001, he joined the Mood and Anxiety Disorders Program at NIMH. His achievements and awards include the Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department of Psychiatry, Harvard Medical School; Outstanding Psychiatrist Research Award, Massachusetts Psychiatric Association; Program for Minority Research Training in Psychiatry, APA; the National Alliance for Research on Schizophrenia and Depression Young Investigator Award; National Alliance for Research on Schizophrenia and Depression Independent Investigator Award; and the National Institutes of Health Director’s Award Scientific/Medical. Dr. Zarate has been elected to membership to the American College of Neuropsychopharmacology. Dr. Zarate’s research focuses on the pathophysiology and development of novel therapeutics for treatment-resistant mood disorders as well as the study of biosignatures of treatment response.